A groundbreaking study shows that GLP-1 diabetes drugs may reduce the risk of obesity-related cancers by 7% compared to DPP-4 inhibitors, particularly in women. Discover the implications for diabetes treatment!
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
Scientists have uncovered a natural method to regulate blood sugar levels by enhancing gut microbes, potentially reducing sugar cravings like popular diabetes drugs. This groundbreaking research could transform diabetes prevention strategies.
Discover how a new study suggests that Ozempic, a drug commonly used for diabetes and weight loss, may also help reduce alcohol consumption and cravings in individuals with alcohol-use disorder.
